We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · January 06, 2022

ASH 2021: GMMG-HD7 Trial Demonstrates Benefits of Adding Isatuximab to Chemotherapy for Newly Diagnosed Multiple Myeloma

The addition of isatuximab did not affect safety or the need for dose reductions of chemotherapy

PracticeUpdate Editorial Team


Further Reading